NEW YORK (GenomeWeb News) — Indiana-based start-up Kylin Pharmaceuticals has licensed the rights to use more than 12 RNAi-related patents from the Purdue Research Foundation to develop drugs, the Foundation said today.
Kylin has received start-up capital from the Indiana venture group IN-vivo Ventures, and from the Research Triangle Park, NC-based Golden Pine Ventures. The company initially plans to focus its efforts on developing therapeutics for cancer, and for viral diseases such as AIDS later.
The Foundation said the pRNA technology it has licensed to Kylin can be used to help deliver targeted RNA-based therapeutics at certain genes.
The IP was invented and developed by a former Purdue professor Peixuan Guo, who is now a director of the Nanomedicine Bionanotechnology Center at the University of Cincinnati. Guo is one of Kylin’s founders and is chairman of the company’s scientific advisory board.
Financial terms of the agreement were not released.